%A Sun Yueqin, Li Aimin, Luo Yue, Song Zhenghui, Zhuang Xuefen, Dai Guanqi, Liu Xinhui %T Efficacy prediction and molecular mechanism of thyroid hormone levels and multi-target TKI therapy for renal cell carcinoma and hepatocellular carcinoma %0 Journal Article %D 2019 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2019.05.011 %P 303-306 %V 46 %N 5 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_10639.shtml} %8 2019-05-08 %X Hypothyroidism is a common adverse reaction in clinical multi-target tyrosine kinase inhibitor (TKI) and may be used as a predictor of efficacy of TKI drugs. Studies show that hypothyroidism is significantly associated with good prognosis in patients with renal cell carcinoma treated with multi-target TKI, which may be related to inhibition of vascular endothelial growth factor receptor pathway, potential offtarget effects and inhibition of cell proliferation. Whereas in the patients with hepatocellular carcinoma who received multi-target TKI therapy, hypothyroidism is an indicator of poor prognosis, which is related to the T3/TR pathway regulating liver cancer growth and invasion. The predictive function and mechanism of thyroid hormone levels in different tumor patients receiving multi-target TKI drugs are different, and further research is still needed.